MacroGenics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

CEO

Eric Risser

CEOEric Risser

Employees

293

Employees293

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2000

Founded2000

Employees

293

Employees293

MGNX Key Statistics

Market cap

219.59M

Market cap219.59M

Price-Earnings ratio

-2.91

Price-Earnings ratio-2.91

Dividend yield

—

Dividend yield—

Average volume

907.35K

Average volume907.35K

High today

$3.86

High today$3.86

Low today

$3.31

Low today$3.31

Open price

$3.49

Open price$3.49

Volume

1.22M

Volume1.22M

52 Week high

$3.86

52 Week high$3.86

52 Week low

$1.02

52 Week low$1.02

Stock Snapshot

MacroGenics(MGNX) stock is priced at $3.40, giving the company a market capitalization of 219.59M. It carries a P/E multiple of -2.91.

On 2026-04-08, MacroGenics(MGNX) stock moved within a range of $3.31 to $3.86. With shares now at $3.40, the stock is trading +2.7% above its intraday low and -11.9% below the session's peak.

Trading activity shows a volume of 1.22M, compared to an average daily volume of 907.35K.

Over the past 52 weeks, MacroGenics(MGNX) stock has traded between a high of $3.86 and a low of $1.02.

MGNX News

TipRanks 6h

MacroGenics Resumes LINNET Trial After FDA Hold Lifted

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 7h

MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study

MacroGenics (MGNX) announced that the U. S. FDA has removed the partial clinical hold on the company’s Phase 2 LINNET study of lorigerlimab, an investigational,...

Simply Wall St 17h

April 2026's Most Promising Penny Stocks

The U.S. market has experienced a notable climb, rising 1.2% in the last week and 33% over the past year, with earnings projected to grow significantly in the c...

Analyst ratings

67%

of 6 ratings

Buy

33.3%

Hold

66.7%

Sell

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.